Get the Stockscreener App
2.4235
6.25%
0.0235
Lisata Therapeutics Inc stock is traded at $2.4235, with a volume of 8,448.
It is up +6.25% in the last 24 hours and down -3.04% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$2.40
Open:
$2.59
24h Volume:
8,448
Relative Volume:
0.70
Market Cap:
$22.18M
Revenue:
-
Net Income/Loss:
$-20.74M
P/E Ratio:
-0.9655
EPS:
-2.51
Net Cash Flow:
$-18.90M
1W Performance:
+3.66%
1M Performance:
-3.04%
6M Performance:
-1.16%
1Y Performance:
-22.73%
1-Day Range:
$2.4235
$2.6663
1-Week Range:
$2.3536
$2.7064
52-Week Range:
$1.87
$4.20
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
2.4235 | 22.18M | 0 | -20.74M | -18.90M | -2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.12 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
515.07 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.50 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
544.26 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.48 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
H.C. Wainwright maintains Lisata Therapeutics stock rating on AI partnership By Investing.com - Investing.com India
Lisata and GATC to use AI for new opioid use disorder drug - The Pharma Letter
Lisata collaborates with GATC Health on drug development - Yahoo
Market movers: T-Mobile, Sunrun, First Solar, Lisata Therapeutics... - Proactive financial news
Lisata Therapeutics to lead development of opioid use disorder drug under expanded alliance - Proactive Investors
Lisata Therapeutics Advances Certepetide for Cancer Treatment - TipRanks
Lisata Therapeutics (LSTA) Partners with GATC Health to Boost Drug Development | LSTA Stock News - GuruFocus
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development | LSTA Stock News - GuruFocus
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development - GlobeNewswire
Lisata Therapeutics Amends Executive Employment Agreements - TipRanks
Lisata Therapeutics to Present at the 2025 BIO International Convention | LSTA Stock News - GuruFocus
Lisata Therapeutics to Present at the 2025 BIO International Convention - The Manila Times
Lisata CEO to Reveal Latest Cancer Treatment Developments at Major Biotech Conference - Stock Titan
Lisata Therapeutics CEO to present at 2025 BIO International Convention - Proactive financial news
Citadel Advisors LLC Makes New $69,000 Investment in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Kalkine : Lisata Therapeutics Earnings Per Share Reflects Biotech Market Trends - Kalkine Media
Lisata Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Lisata Therapeutics (NASDAQ:LSTA) Trading Down 2.2% – What’s Next? - Defense World
Dimensional Fund Advisors LP Increases Stock Position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) - Defense World
Lisata outlines data-rich year ahead with multiple clinical milestones for Certepetide - MSN
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call Transcript - Insider Monkey
Lisata Therapeutics’ Earnings Call Highlights Progress - TipRanks
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ... - Yahoo Finance
Earnings call transcript: Lisata Therapeutics sees improved Q1 2025 performance - Investing.com
Lisata Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lisata eyes key trial milestones in 2025 as certepetide development gains momentum - Proactive financial news
Lisata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025 - The Manila Times
Lisata Therapeutics to Report First Quarter 2025 Financial - GlobeNewswire
Lisata Therapeutics Earnings: Solid Tumor Treatment Developer Reports Q1 2025 Results May 8 - Stock Titan
Will Lisata Therapeutics (NASDAQ:LSTA) Spend Its Cash Wisely? - Yahoo Finance
LSTALisata Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Lisata Therapeutics (NASDAQ:LSTA) Shares Up 0.9% – Still a Buy? - Defense World
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalant license agreement - Proactive financial news
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive Investors
Market movers: Meta, HPE, Applied Digital, Lisata Therapeutics... - Proactive Investors
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Lisata falls after mid-stage data for anticancer agent - MSN
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’ - marketscreener.com
Neostem stock plunges to 52-week low at $2.01 amid market challenges - Investing.com Australia
Neostem stock plunges to 52-week low at $2.01 amid market challenges By Investing.com - Investing.com South Africa
Healthcare investment strategies reshaped by inflation, interest rates and M&A in 2025 - Proactive financial news
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR.com
Lisata Therapeutics CEO discusses AI drug discovery collaborationICYMI - Proactive Investors
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):